{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:10:52Z","timestamp":1778764252365,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106741","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:53:10Z","timestamp":1757519590000},"page":"106741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment discontinuation in older patients with multiple sclerosis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-9144","authenticated-orcid":false,"given":"Jessica","family":"Frau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doriana","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Lapucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Saporito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Di Gianvito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Atzei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolama","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106741_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102816","article-title":"Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis","volume":"50","author":"Naseri","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106741_bib0002","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.msard.2025.106741_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379538","article-title":"Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review","volume":"15","author":"Fern\u00e1ndez","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.msard.2025.106741_bib0004","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/1352458514561904","article-title":"The changing face of multiple sclerosis: Prevalence and incidence in an aging population","volume":"21","author":"Solaro","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2025.106741_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102815","article-title":"Multiple sclerosis and aging: comorbidity and treatment challenges","volume":"50","author":"Ostolaza","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106741_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103406","article-title":"Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age","volume":"57","author":"Jakimovski","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.msard.2025.106741_bib0007","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1007\/s00415-024-12384-3","article-title":"Management of multiple sclerosis in older adults: review of current evidence and future perspectives","volume":"271","author":"DiMauro","year":"2024","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.msard.2025.106741_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2025.106741_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578368","article-title":"As time goes by: Treatment challenges in elderly people with multiple sclerosis","volume":"391","author":"Gelibter","year":"2024","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2025.106741_bib0010","first-page":"577","article-title":"Meta-analysis of the Age-Dependent Efficacy of","volume":"8","author":"Weideman","year":"2017","journal-title":"Multiple Sclerosis Treatments. Front Neurol"},{"key":"10.1016\/j.msard.2025.106741_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of disease modifying therapy benefits and risks: an argument for De-escalation as a treatment paradigm for patients with multiple sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front. Neurol"},{"issue":"6","key":"10.1016\/j.msard.2025.106741_bib0012","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ene.12690","article-title":"Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials","volume":"22","author":"Signori","year":"2015","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.msard.2025.106741_bib0013","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2025.106741_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.829331","article-title":"Late-Onset MS: Disease Course and Safety-Efficacy of DMTS","volume":"13","author":"Buscarinu","year":"2022","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.msard.2025.106741_bib0015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1177\/1352458520964778","article-title":"Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression","volume":"27","author":"Prosperini","year":"2021","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2025.106741_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106741_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16289","article-title":"Real-world persistence of multiple sclerosis disease-modifying therapies","volume":"31","author":"Tallantyre","year":"2024","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106741_bib0018","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.msard.2025.106741_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/13524585241303489","article-title":"DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial","volume":"31","author":"Corboy","year":"2025","journal-title":"Mult scler"},{"issue":"11","key":"10.1016\/j.msard.2025.106741_bib0020","first-page":"1248","article-title":"Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States","volume":"30","author":"Qian","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.msard.2025.106741_bib0021","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping Disease-Modifying Treatments in Multiple Sclerosis: a Systematic Review and Meta-Analysis of Real-World Studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2025.106741_bib0022","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/01616412.2022.2124792","article-title":"Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM","volume":"45","author":"Gisela","year":"2023","journal-title":"Neurol Res"},{"issue":"5","key":"10.1016\/j.msard.2025.106741_bib0023","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2025.106741_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107612","article-title":"Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression","volume":"225","author":"Salavisa","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.msard.2025.106741_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00415-022-11341-2","article-title":"Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis","volume":"270","author":"Chappuis","year":"2023","journal-title":"J Neurol"},{"issue":"17","key":"10.1016\/j.msard.2025.106741_bib0026","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106741_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102724","article-title":"Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?","volume":"49","author":"Lynch","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106741_bib0028","article-title":"Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE","volume":"1","author":"Donz\u00e9","year":"2015","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"10.1016\/j.msard.2025.106741_bib0029","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7224\/1537-2073.2012-034","article-title":"Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database","volume":"15","author":"Fox","year":"2013","journal-title":"Int J MS Care"},{"issue":"12","key":"10.1016\/j.msard.2025.106741_bib0030","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2025.106741_bib0031","first-page":"awae409","article-title":"De-escalating and discontinuing disease-modifying therapies in multiple sclerosis","volume":"21","author":"Androdias","year":"2024","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2025.106741_bib0032","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1007\/s00415-023-12152-9","article-title":"Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry","volume":"271","author":"Lorefice","year":"2024","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.msard.2025.106741_bib0033","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/brain\/awaa251","article-title":"Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis","volume":"143","author":"Amato","year":"2020","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2025.106741_bib0034","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200167","article-title":"Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity","volume":"10","author":"Bose","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"updated-by":[{"DOI":"10.1016\/j.msard.2026.107170","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000}},{"DOI":"10.1016\/j.msard.2026.107170","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:21:02Z","timestamp":1774999262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S2211034825004833"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106741","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment discontinuation in older patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106741"}}